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A B S T R A C T
Background: Two vitamin D pregnancy supplementation trials were recently undertaken in South
Carolina: The NICHD (n = 346) and Thrasher Research Fund (TRF, n = 163) studies. The ﬁndings suggest
increased dosages of supplemental vitamin D were associated with improved health outcomes of both
mother and newborn, including risk of preterm birth (<37 weeks gestation). How that risk was
associated with 25(OH)D serum concentration, a better indicator of vitamin D status than dosage, by
race/ethnic group and the potential impact in the community was not previously explored. While a
recent IOM report suggested a concentration of 20 ng/mL should be targeted, more recent work suggests
optimal conversion of 25(OH)D–1,25(OH)2D takes place at 40 ng/mL in pregnant women.
Objective: Post-hoc analysis of the relationship between 25(OH)D concentration and preterm birth rates
in the NICHD and TRF studies with comparison to Charleston County, South Carolina March of Dimes (CC-
MOD) published rates of preterm birth to assess potential risk reduction in the community.
Methods: Using the combined cohort datasets (n = 509), preterm birth rates both for the overall
population and for the subpopulations achieving 25(OH)D concentrations of 20 ng/mL, >20 to <40 ng/
mL, and 40 ng/mL were calculated; subpopulations broken down by race/ethnicity were also examined.
Log-binomial regression was used to test if an association between 25(OH)D serum concentration and
preterm birth was present when adjusted for covariates; locally weighted regression (LOESS) was used to
explore the relationship between 25(OH)D concentration and gestational age (weeks) at delivery in more
detail. These rates were compared with 2009–2011 CC-MOD data to assess potential risk reductions in
preterm birth.
Results: Women with serum 25(OH)D concentrations 40 ng/mL (n = 233) had a 57% lower risk of preterm
birth compared to those with concentrations 20 ng/mL [n = 82; RR = 0.43, 95% conﬁdence interval
(CI) = 0.22,0.83]; this lower risk was essentially unchanged after adjusting for covariates (RR = 0.41, 95%
CI = 0.20,0.86). The ﬁtted LOESS curve shows gestation week at birth initially rising steadily with
increasing 25(OH)D and then plateauing at 40 ng/mL. Broken down by race/ethnicity, there was a 79%
lower risk of preterm birth among Hispanic women with 25(OH)D concentrations 40 ng/mL (n = 92)
compared to those with 25(OH)D concentrations 20 ng/mL (n = 29; RR = 0.21, 95% CI = 0.06,0.69) and a
45% lower risk among Black women (n = 52 and n = 50; RR = 0.55, 95% CI = 0.17,1.76). There were too few
white women with low 25(OH)D concentrations for assessment (n = 3). Differences by race/ethnicity
were not statistically signiﬁcant with 25(OH)D included as a covariate.
Compared to the CC-MOD reference group, women with serum concentrations 40 ng/mL in the
combined cohort had a 46% lower rate of preterm birth overall (n = 233, p = 0.004) with a 66% lower rate
among Hispanic women (n = 92, p = 0.01) and a 58% lower rate among black women (n = 52, p = 0.04).
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Conclusions: In this post-hoc analysis, achieving a 25(OH)D serum concentration 40 ng/mL signiﬁcantly
decreased the risk of preterm birth compared to 20 ng/mL. These ﬁndings suggest the importance of
raising 25(OH)D levels substantially above 20 ng/mL; reaching 40 ng/mL during pregnancy would reduce
the risk of preterm birth and achieve the maximal production of the active hormone.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Since its discovery a hundred years ago, vitamin D has emerged
as one of the most controversial nutrients and prohormones of the
21st century. Its role in calcium metabolism and bone health is
undisputed but its role in immune function and long-term health is
still debated. There are clear indicators from in vitro and animal in
vivo studies that point to the role of vitamin D in both innate and
adaptive immunity [1–3], and an emerging number of observa-
tional and cohort studies that support vitamin D’s role in
pregnancy outcomes [4,5]; however, translation of these ﬁndings
to clinical practice, including the care of pregnant women, has not
yet fully materialized. Until recently, there has been a paucity of
data from randomized controlled trials to establish clear-cut
beneﬁcial effects of vitamin D supplementation or concentration of
circulating 25(OH)D during pregnancy.
The current vitamin D requirements during pregnancy as
established by the Institute of Medicine’s (IOM) 2010 guidelines
are 400 IU/day as the Estimated Average Requirement (EAR) and
600 IU/day as the Recommended Dietary Allowance (RDA) [6].
Sufﬁciency is deﬁned by the IOM as a total circulating 25(OH)D
concentration of at least 20 ng/mL [6]. While the IOM guidelines
focus speciﬁcally on bone health, these recommendations are
widely interpreted as covering all health conditions. Recent
observational studies have shown that there exists a large
proportion of women who, despite achieving the EAR intake for
vitamin D, have 25(OH)D concentrations below 20 ng/mL, includ-
ing a disproportionately high number of African American and
Hispanic women [7–9].
Two vitamin D pregnancy supplementation trials were recently
conducted in South Carolina to determine the optimal vitamin D
supplementation regimen necessary to achieve sufﬁciency in
pregnant women [deﬁned a priori in the NICHD and Thrasher
Research Fund (TRF) studies [10–12] as a total circulating 25(OH)D
level 32 ng/mL or greater; deﬁciency as less than 20 ng/mL; and
insufﬁciency as 20 to <32 ng/mL]. In those trials, 4000 IU vitamin
D/day was found to safely achieve a level of at least 32 ng/mL by
early in the second trimester in a diverse group of pregnant
women. While 1,25(OH)2D can be normal when 25(OH)D is quite
low in non-pregnant individuals, only during pregnancy is 25(OH)
D directly related to 1,25(OH)2D. Speciﬁcally, in the NICHD trial, it
was found that the conversion of 25(OH)D to the active form of the
hormone, 1,25(OH)2D, plateaued around 40 ng/mL [10]. Further,
the impact on pregnancy health, including risk of preterm birth
(<37 weeks gestation), was explored with ﬁndings suggestive that
improved vitamin D status was associated with improved health
outcomes of both mother and newborn [12,13].
While higher vitamin D dose regimens were suggestive of a
reduced risk of preterm birth [10,12,13], the relationship between
preterm birth and 25(OH)D serum concentration was not
previously explored in detail. Due to multiple input sources and
inter-individual variability in dose response [14], 25(OH)D serum
concentration is a better indicator of vitamin D status than dose.
The objective of this post-hoc analysis was to examine if an
association between 25(OH)D concentration and preterm birth
incidence exists within the combined NICHD and TRF cohort both
overall and among speciﬁc race/ethnic groups, and if so, to
compare the rates to the Charleston County, South Carolina March
of Dimes (CC-MOD) published rates of preterm birth (most
recently updated in 2011 at the time of this analysis) to assess
potential risk reduction in the community [15].
2. Methods
2.1. Study design
As previously reported, datasets from the NICHD and TRF
vitamin D supplementation trials were combined for this analysis
using a common data dictionary [13]. Details about both clinical
trials and results based on dosage have been published previously
[10,12]. Brieﬂy, the studies were conducted concurrently and
administered identical questionnaires to produce comparable
sociodemographic and clinical characteristics using the same
criteria. In the NICHD trial, women with baseline 25(OH)D
concentrations 40 ng/mL were randomized to one of three
treatment groups: control (400 IU vitamin D3/day), 2000 IU/day, or
4000 IU/day. Women with concentrations >40–60 ng/mL (n = 22)
were randomized to 400 or 2000 IU/day and women with
concentrations >60 ng/mL (n = 1) were given 400 IU/day. In the
TRF trial, women were randomized to either 2000 IU/day or
4000 IU/day without exclusion. Outcome measures for both
clinical trials included the following: [1] maternal baseline and
delivery 25(OH)D [2]; neonatal 25(OH)D concentration; and [3]
gestational age at delivery in weeks. This post-hoc analysis
included women who participated in either the NICHD trial or
the TRF trial and were followed through delivery and had blood
samples available within 6 weeks of delivery (n = 509).
2.2. Deﬁnition of preterm birth
Information on gestational age was based on the mother’s
report of the ﬁrst day of her last menstrual period generating the
obstetrical Expected Date of Conﬁnement or Delivery (EDC or EDD)
with ultrasound conﬁrmation at the time of mother’s ﬁrst
obstetrical visit. All women were enrolled in either the NICHD
trial or the TRF trial <16 weeks of gestation and thus ultrasound
conﬁrmation of dating was within the ﬁrst trimester/early second
trimester. Preterm birth was deﬁned as delivery of a liveborn infant
at <37 completed weeks of gestation.
2.3. Laboratory measurements
Maternal and cord blood/neonatal total circulating 25(OH)D
assays—a rapid, direct RIA developed in the Hollis laboratory and
manufactured by Diasorin Corporation (Stillwater, MN) was used
to measure total circulating 25(OH)D concentration in serum
samples as previously described [10]. The laboratory participated
in an independent quality assessment/assurance program (DEQAS)
using National Institute of Standards and Technology (NIST)
standards in place throughout both clinical trials [16]. The inter-
and intra-assay coefﬁcient of variation was 10%.
2.4. Statistical analyses
Baseline demographic characteristics for the NICHD and TRF
cohorts were summarized and compared using chi-square tests for
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categorical variables (race/ethnicity, insurance status, marital
status, education level, and preterm birth), Mann–Whitney tests
for maternal age, Poisson regression for count data (parity and
gravidity), and t-tests for baseline maternal 25(OH)D. Serum 25
(OH)D concentrations were plotted against gestation week at birth
and locally weighted regression (LOESS) was used to explore the
relationship in more detail.
Two 25(OH)D concentrations were of special interest: 20 ng/
mL, from the IOM guidelines, and 40 ng/mL, from the 25(OH)D
concentration found to achieve maximal production of the active
hormone 1,25(OH)2D [10]. Preterm birth rates were calculated
both for the overall population and among women achieving 25
(OH)D concentrations of 20 ng/mL, >20 to <40 ng/mL, and
40 ng/mL within 6 weeks of delivery. The incidence of preterm
birth across 25(OH)D group was tested for a trend and risk ratios
and 95% conﬁdence intervals were calculated.
Univariate log-binomial regression was used to identify
covariates for multivariate analysis. Covariates tested included
race/ethnicity, maternal age, parity, gravidity, insurance status,
marital status, education level, and study. Multivariable log-
binomial regression was conducted within the combined cohort to
estimate risk ratios and 95% conﬁdence intervals for the
association between 25(OH)D serum concentration and the risk
of preterm birth, adjusting for the effect of covariates with a
univariate association of p < 0.20. Participants with a race of
“other” were excluded due to small cell sizes. To identify
differences by race/ethnic group, preterm birth rates were
calculated for each race/ethnic group for those with serum
concentrations 20 ng/mL vs. 40 ng/mL. These rates were then
compared to the CC-MOD 2009–2011 data to assess potential risk
reduction in the community [15].
3. Results
The characteristics of the combined NICHD/TRF cohort are
found in Table 1. In these diverse groups of women, there were
signiﬁcant differences between the NICHD and TRF cohorts by
race/ethnicity, maternal age, parity, gravidity, insurance status,
marital status, and education level but not baseline 25(OH)D or
proportion of preterm births.
Within the combined cohort, there were 50 preterm births (<37
weeks) (10%), of which 7 were very preterm (<32 weeks), 5 were
moderately preterm (32 to <34 weeks), and 38 were late preterm
(34 to <37 weeks). A plot of gestation week at birth as a function of
25(OH)D concentration with preterm status and cut points of
interest highlighted is shown in Fig. 1, with the ﬁtted LOESS curve
superimposed.
Preterm birth rates were 17% in women with 25(OH)D 20 ng/
mL (N = 82); 10% in women with 25(OH)D >20 to <40 ng/mL
(N = 194), and 7% in women with 25(OH)D 40 ng/mL (N = 233).
Those with serum 25(OH)D concentrations 40 ng/mL within 6
weeks of delivery had a 57% lower risk of preterm birth compared
to those with concentrations 20 ng/mL (RR = 0.43, 95% CI =
0.22,0.83), without adjustment for covariates (Table 2). Among
women with low baseline 25(OH)D concentrations (20 ng/mL) at
the beginning of their pregnancy (n = 208), those who achieved
40 ng/mL within 6 weeks of delivery (n = 60) had a 78% lower risk
of preterm birth compared to those who did not (RR = 0.22, 95%
CI = 0.05,0.92).
A zoom on the ﬁtted LOESS curve with conﬁdence bounds
superimposed to better display the average behavior across its
dynamic range shows gestational age at birth initially rising
steadily with increasing 25(OH)D concentration and then plateau-
ing at approximately 40 ng/mL (Fig. 2). Box plots showing 25(OH)D
concentration by birth category are shown in Supplementary Fig. 1.
The median 25(OH)D within 6 weeks of delivery for those with a
preterm birth (<37 weeks) was 31 ng/mL compared to 39 ng/mL
for those with a term birth (p = 0.01).
Within the combined cohort, serum 25(OH)D, race/ethnicity,
maternal age, and insurance status each had associations of
p < 0.20 with preterm birth in univariate log-binomial regression
analyses and were included in the multivariable log-binomial
regression model. Parity, gravidity, marital status, education level,
and study had univariate associations of p  0.20. In multivariable
log-binomial regression, the only variable signiﬁcantly associated
with preterm birth was 25(OH)D serum concentration. After
adjusting for race/ethnicity, maternal age, and insurance status,
participants with 25(OH)D concentrations 40 ng/mL had a 59%
lower risk of preterm birth than participants with concentrations
20 ng/mL (RR = 0.41, 95% CI = 0.20,0.86) (Table 2). There was a
non-signiﬁcant decrease in risk (41%) between those with
Table 1
Maternal sociodemographic and clinical characteristics of cohort.
Characteristic Combined cohort
(N = 509)
NICHD cohort
(N = 346)
TRF cohort
(N = 163)
p-Valuea
(comparing NICHD vs. TRF)
Race/ethnicity (N, %) <0.0001
Hispanic 207 (41%) 137 (40%) 70 (43%)
Black 169 (33%) 96 (28%) 73 (45%)
White 129 (25%) 113 (33%) 16 (10%)
Other 4 (1%) 0 (0%) 4 (3%)
Maternal age, years (median and range) 26 (16–44) 26 (16–44) 24 (16–39) <0.0001
Parity (median and range) 1 (0–9) 2 (0–9) 1 (0–4) <0.0001
Gravidity (median and range)b 2 (1–9) 2 (1–9) 2 (1–6) <0.0001
Insurance status (N, %)b <0.0001
None/Medicaid 342 (68%) 214 (63%) 128 (79%)
Marital status (N, %)b <0.0001
Married 234 (46%) 178 (52%) 56 (34%)
Education level (N, %)b <0.0001
Some college or higher 267 (54%) 213 (65%) 54 (33%)
Baseline maternal 25(OH)D, ng/mL 0.47
Mean (SD) 23 (9.7) 24 (9.7) 23 (9.6)
Birth Outcome (N, %) 0.20
Preterm (<37 weeks) 50 (10%) 30 (9%) 20 (12%)
a Statistical comparison of characteristics between NICHD and Thrasher Research Fund (TRF) cohorts. Race, insurance status, marital status, education level, and birth
outcome compared using chi-square tests. Maternal age compared using Mann–Whitney test. Parity and gravidity compared using Poisson regression. Baseline maternal 25
(OH)D compared using t-test.
b 24 participants missing gravidity data, 4 missing insurance status data, 2 missing marital status data, and 17 missing education level data.
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concentrations >20 to <40 ng/mL compared to those with
concentrations 20 ng/mL (RR = 0.59, 95% CI = 0.31,1.14).
Among race/ethnic groups in the combined cohort, the
percentage of preterm birth was 8% among Hispanic women,
13% among black women, and 9% among white women.
Supplementary Fig. 2 shows the plots of gestational age at birth
as a function of 25(OH)D concentration by race/ethnic group, with
ﬁtted LOESS curves superimposed. There was a 79% reduction in
preterm birth among Hispanic women who attained 40 ng/mL
compared to those 20 ng/mL (RR = 0.21, 95% CI = 0.06, 0.69), and a
45% reduction among black women (RR = 0.55, 95% CI = 0.17,1.76). In
white women, there were not enough women with low 25(OH)D
concentrations within 6 weeks of delivery for assessment (n = 3).
Differences by race/ethnicity were not statistically signiﬁcant
when 25(OH)D concentration was included as a covariate in
multivariable regression analysis.
Compared to the CC-MOD reference group, women in the
combined cohort with serum 25(OH)D concentrations 40 ng/mL
had a 46% lower rate of preterm birth (p = 0.004) (Fig. 3). Among
race/ethnic groups, rates were reduced by 66% for Hispanic
women (p = 0.01), 58% for black women (p = 0.04), and 11% for
white women (p = 0.77). While the 25(OH)D status of the CC-MOD
population is not known, as a surrogate measurement for that
population, we found that women in the combined cohort control
group who received 400 IU/day (the current standard of vitamin D
supplementation for pregnant women) and who had a median
achieved 25(OH)D concentration of 30 ng/mL had rates of preterm
birth that were not signiﬁcantly different from the CC-MOD
population: 9%, 14%, 11%, and 11% for Hispanic, black, white, and all
women combined respectively. The data and code used to
generate the analyses are available to qualiﬁed researchers upon
request.
4. Discussion
In this post-hoc analysis of the combined cohort dataset from
two pregnancy vitamin D supplementation trials, there was a clear
association between 25(OH)D serum concentration within six
weeks of delivery and preterm birth. Achieving a 25(OH)D serum
concentration of 40 ng/mL signiﬁcantly decreased the risk of
20 40 60 80 10 0
30
35
40
Serum 25 (OH)D (ng/mL)
G
es
ta
tio
n 
W
ee
k 
at
 B
irt
h
Term
Late Preterm
Mode rately Preterm
Very Preterm
Fig.1. 25(OH)D concentration within 6 weeks of delivery by gestational age (weeks) at birth (NICHD & TRF, N = 509). Term birth is 37 weeks of gestation; late preterm birth is
34 to <37 weeks; moderately preterm is 32 to <34 weeks; and very preterm is <32 weeks. White circles represent women assigned to the control group (400 IU/day); gray
triangles represent women assigned to the 2000 IU/day treatment group; and solid black squares represent women assigned to the 4000 IU/day treatment group. Black line
represents ﬁtted LOESS curve.
Table 2
Association between serum 25(OH)D concentration within 6 weeks of delivery and the risk of preterm birth (NICHD & TRF, N = 509).
Preterm birth
(<37 Weeks)
Term birth
(37 Weeks)
p-Value
(test for trend)
Unadjusted RR
(95% CI)
Adjusteda RR
(95% CI)
20 ng/mL 14 (17%) 68 (83%) 0.01 1.0 1.0
(N, %)
>20 to <40 ng/mL 19 (10%) 175 (90%) 0.57
(0.30, 1.09)
0.59
(0.31,1.14)(N,%)
40 ng/mL 17 (7%) 216 (93%) 0.43
(0.22, 0.83)
0.41
(0.20, 0.86)(N, %)
Bold values signify signiﬁcance at p < 0.05.
a Adjusted for race/ethnicity, maternal age, and insurance status.
248 C.L. Wagner et al. / Journal of Steroid Biochemistry & Molecular Biology 155 (2016) 245–251
preterm birth compared to 20 ng/mL. While women with 25(OH)
D concentrations between 20 and 40 ng/mL also had a decreased
risk of preterm birth, it was less of a decrease (41% vs. 59% in
women with 25(OH)D 40 ng/mL) and it was not statistically
signiﬁcant. These ﬁndings support the premise that 25(OH)D
concentrations of 40 ng/mL and above are needed to signiﬁcantly
reduce the risk of preterm birth. In subgroup analyses, the
reduction in risk was most notable among those with baseline 25
(OH)D 20 ng/mL and among Hispanic women. When compared
to published 2009–2011 CC-MOD rates of preterm birth [15], there
were signiﬁcant reductions in risk for Hispanic and black women
40 ng/mL but there was not a statistically signiﬁcant reduction
for white women. These results suggest the importance of vitamin
D status during pregnancy.
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Fig. 2. Zoom on the ﬁtted LOESS curve of 25(OH)D concentration and gestational age (weeks) at birth to better show the change in average behavior with 1 and 2 SD windows
superimposed (NICHD & TRF, N = 509). Black line represents ﬁtted LOESS curve; dark gray area represents 1 standard deviation; and light gray area represents 2 standard
deviations. Multivariable log-binomial regression found that 25(OH)D concentrations 40 ng/mL reduces the risk of preterm birth by 59% compared to 20 ng/mL, adjusted
for covariates.
4.3%
Fig. 3. Comparison of preterm birth rates for Charleston County, South Carolina March of Dimes (CC-MOD) vs. NICHD & TRF combined cohort. CC-MOD rates are the published
average percent of preterm births among live births for 2009–2011 in Charleston County, South Carolina; 25(OH)D concentrations unknown [15]. Combined cohort includes
participants from 2 studies conducted in South Carolina [10,12]. Percent lower risk and p-value between CC-MOD and combined cohort with 25(OH)D 40 ng/mL. *p < 0.05.
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A concern that women who deliver prematurely also have lower
25(OH)D concentrations due to less time during gestation for
vitamin D supplementation to improve vitamin D status has been
raised [17]. Women taking 400 IU/day of vitamin D, as well as those
on higher doses, reach steady-state by 2 months of supplementa-
tion [10]. The association in this post-hoc and earlier analyses
utilized the 25(OH)D within six weeks of delivery. In a recent
publication [4], it was shown that the 25(OH)D concentration
closest to the time of delivery, especially in Hispanic women, had a
stronger association with gestational age and prematurity than
baseline or second trimester 25(OH)D, arguing that the effect is
mutable and that even in those women who were deﬁcient at
baseline, vitamin D supplementation can affect outcome.
Other studies have found a similar reduction in risk of preterm
birth. A recent study by Bodnar et al. [5] found a 1.8-fold (95%
CI = 1.3,2.6) increase in the risk of preterm birth among those with
25(OH)D <20 ng/mL compared to 30 ng/mL and that the risk of
preterm birth signiﬁcantly decreased as 25(OH)D concentration
increased to about 36 ng/mL. In NICHD pregnancy vitamin D
supplementation trial by Hollis et al., the conversion of 25(OH)D to
1,25(OH)2D, the active hormonal form of vitamin D, was optimized
at 40 ng/mL [10]. There were no reported safety issues at such
higher 25(OH)D concentrations. The Institute of Medicine recom-
mends that pregnant women attain a total circulating 25(OH)D
concentration of at least 20 ng/mL [6]; however, these ﬁndings
suggest that higher levels can be beneﬁcial for birth outcomes. This
post hoc analysis supports this premise.
The lack of a visible risk reduction trend among white
participants was likely due to the lack of women with low 25
(OH)D levels within 6 weeks of delivery in this race group. Also,
white participants in this combined cohort started out with
relatively high baseline 25(OH)D concentrations (median = 30 ng/
mL), which likely left little opportunity for improvement. Black
women had a median baseline 25(OH)D of 16 ng/mL, but only
increased to a median of 30 ng/mL, which was likely too low to see
a statistically signiﬁcant change in risk. Comparatively, Hispanic
women started with a median baseline 25(OH)D of 24 ng/mL and
achieved a median 25(OH)D of 38 ng/mL, a change in nutrient
status that better spans the response region seen in Bodnar et al.
[5,18,19].
Strengths of this analysis include using serum 25(OH)D
concentration as the predictor variable, which is statistically more
powerful than using treatment group because it accounts for all
input sources including cutaneous, food, and supplementation
whereas treatment group only accounts for supplemental dose.
Also, using 25(OH)D concentration overcomes the inherent bias of
compliance and inter-individual variability in response to dose
associated with treatment group analyses. Additionally, this
randomized trial used supplementation doses ten times higher
than the IOM recommendation of 400 IU/day, and therefore a
larger spectrum of 25(OH)D concentrations could be assessed in
relation to preterm birth risk.
The limitations of this post-hoc analysis are that this was a post-
study analysis that was not able to control for some covariates
related to preterm birth such as body mass index (BMI) and other
sociodemographic factors such as smoking and alcohol use (which
was extremely low in this cohort). Observed differences by race for
those 20 ng/mL vs. 40 ng/mL within the combined cohort
indicate that socioeconomic factors may play a role and while this
analysis adjusted for insurance status as a proxy for socioeconomic
status, additional indicators were not available. The second issue is
one of generalizability and whether or not the diversity of
socioeconomic backgrounds and racial/ethnic groups of the
women in the study are representative of the larger population.
There is also the limitation of sample size and power, with a larger
sample size necessary to investigate 25(OH)D and race/ethnic
trends further, particularly for white women. Additionally, the
serum concentrations of the CC-MOD comparison population were
unknown. Since the rate of preterm birth in the CC-MOD
population was not signiﬁcantly different from the combined
cohort control group, it is reasonable to expect that women in the
CC-MOD population had a similar average intake of 400 IU vitamin
D per day (the standard amount found in prenatal vitamins) and
serum 25(OH)D concentration averaging 30 ng/mL, the average 25
(OH)D concentration in the control group taking 400 IU vitamin D
per day. Furthermore, knowing that some women opt not to take
prenatal vitamins, it is likely that the mean baseline 25(OH)D
concentration of 23 ng/mL of the combined cohort is even more
representative of the CC-MOD population. The similar rates of
preterm birth strengthen the ﬁnding that improved vitamin D
status was associated with lower rates of preterm births.
This post-hoc analysis supports the importance of attaining a 25
(OH)D blood concentration substantially above 20 ng/mL during
pregnancy for the prevention of preterm birth. Reaching 40 ng/mL
would achieve the optimal conversion of 25(OH)D to 1,25(OH)2D
[10] and lower preterm birth risk. An intake amount substantially
higher than the IOM recommendation of 400 IU/day is needed for
most people to attain this level. Less than one third (29%) of
participants in the control group receiving 400 IU/day achieved a
25(OH)D concentration of 40 ng/mL compared to 57% in the
4000 IU treatment group, a dose amount with no observed adverse
effects. Individuals should aim for a desired 25(OH)D level instead
of taking a generic dose amount since 25(OH)D serum concentra-
tion is a better indicator of vitamin D status. Serum 25(OH)D
testing is recommended to determine the speciﬁc intake amount
an individual needs to attain a speciﬁc 25(OH)D concentration.
The March of Dimes estimates that the annual cost of preterm
births in the United States is $12 billion (for 455,918 children) [20].
If approximately 50% of preterm births could be prevented in the
general population, as this analysis suggests is possible, there
could be $6 billion available for other services and, more than
225,000 children and families spared this trauma. In light of this,
practice guidelines at the Medical University of South Carolina
(MUSC) and other institutions are currently being changed to
prospectively target 40 ng/mL for pregnant women with the goal of
dramatically lowering preterm birth rates.
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